Nutriband Inc. (NASDAQ: NTRB) announced that CEO Gareth Sheridan will attend the inaugural Nasdaq LaB Biotech Summit on Sept. 16, 2026, at Nasdaq MarketSite in New York. The summit will bring together biotechnology executives, investors, and industry leaders for an evening of thought leadership and networking.
This announcement is significant because it places Nutriband at the forefront of discussions on biotech innovation, particularly in the realm of transdermal drug delivery. Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Its lead product under development is an abuse-deterrent fentanyl patch incorporating its AVERSA™ abuse-deterrent technology. This technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The importance of such technology cannot be overstated. The opioid crisis continues to ravage communities worldwide, with fentanyl being a major contributor to overdose deaths. By developing a patch that deters abuse, Nutriband aims to address a critical public health issue. The company’s participation in the Nasdaq summit provides a platform to showcase this innovation to key stakeholders, potentially attracting partnerships and investment that could accelerate development and commercialization.
For investors, this news signals Nutriband’s proactive engagement with the investment community and its commitment to advancing its pipeline. The summit offers a unique opportunity for the company to network with potential collaborators and investors, which could be a catalyst for future growth. As the biotech sector continues to evolve, events like the Nasdaq LaB Biotech Summit are vital for fostering connections and driving innovation.
The broader implications of Nutriband’s technology extend to public health policy and pharmaceutical regulation. If successful, the AVERSA™ technology could set a new standard for transdermal patches, potentially being adopted by other manufacturers to enhance safety across the industry. This could lead to reduced rates of opioid misuse and accidental exposure, ultimately saving lives.
The company’s newsroom provides the latest updates on NTRB at https://ibn.fm/NTRB. The full press release is available at https://ibn.fm/j4F3R. Nutriband’s website is www.nutriband.com.
As the biotech industry gathers in New York, all eyes will be on how companies like Nutriband are leveraging technology to tackle some of the most pressing health challenges of our time. The Nasdaq LaB Biotech Summit represents a convergence of ideas and capital, and Nutriband’s presence underscores its role as a key player in this space.
